Clearmind Briefs FDA on Psychedelic Therapy and Patient Access
VANCOUVER, Canada — September 17, 2026 Clearmind Medicine announced that its Chief of Global Impact, Mary-Elizabeth Gifford, testified at...
psychedelic medicine
Advertisement
Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial
VANCOUVER, Canada — September 11, 2026 Clearmind Medicine Inc. announced that the first patients with Alcohol Use Disorder (AUD)...
Compass Pathways Names U.S. Grant Recipients for COMP360 Training
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
Definium Therapeutics to Present Phase 3 DT120 Data at Psych Congress
NEW YORK — September 10, 2026 Definium Therapeutics, Inc. announced plans to present six posters and an invited oral...
Definium Therapeutics Gains FDA Breakthrough Therapy Designation for DT120 in MDD
NEW YORK — September 8, 2026 Definium Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
Advertisements
Clearmind Advances CMND-100 Into Phase IIa Trial for Alcohol Use Disorder
Vancouver, Canada — September 1, 2026 Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its...
MAPS Responds to FDA Progress on MDMA-Assisted PTSD Therapy
Denver, Colorado, USA — August 10, 2026 Multidisciplinary Association for Psychedelic Studies (MAPS) responded to reports that Resilient Pharmaceuticals,...
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Clearmind Reports Positive Intranasal MEAI Results
Vancouver, Canada, July 16, 2026 Clearmind Medicine announced positive ex vivo results demonstrating enhanced nasal retention for its intranasal...
Advertisement
